Sarah E. James, M.D., Ph.D.

المنشورات

  1. Pepin K, Grimm R, Kargar S, Howe BM, Fritchie K, Frick M, Wenger D, Okuno S, Ehman R, McGee K, James S, Laack N, Herman M, Pafundi D. Soft Tissue Sarcoma Stiffness and Perfusion Evaluation by MRE and DCE-MRI for Radiation Therapy Response Assessment: A Technical Feasibility Study. Biomed Phys Eng Express. 2019 Jul; 5 (4) Epub 2019 May 22
    View PubMed
  2. Lester SC, Lin SH, Chuong M, Bhooshan N, Liao Z, Arnett AL, James SE, Evans JD, Spears GM, Komaki R, Haddock MG, Mehta MP, Hallemeier CL, Merrell KW. A Multi-institutional Analysis of Trimodality Therapy for Esophageal Cancer in Elderly Patients. Int J Radiat Oncol Biol Phys. 2017 Jul 15; 98 (4):820-828 Epub 2017 Feb 20
    View PubMed
  3. Lin SH, Merrell KW, Shen J, Verma V, Correa AM, Wang L, Thall PF, Bhooshan N, James SE, Haddock MG, Suntharalingam M, Mehta MP, Liao Z, Cox JD, Komaki R, Mehran RJ, Chuong MD, Hallemeier CL. Multi-institutional analysis of radiation modality use and postoperative outcomes of neoadjuvant chemoradiation for esophageal cancer. Radiother Oncol. 2017 Jun; 123 (3):376-381 Epub 2017 Apr 25
    View PubMed
  4. Arnett ALH, Merrell KW, Martin Macintosh E, Macintosh EM, James SE, Nathan MA, Shen KR, Ravi K, Neben Wittich MA, Haddock MG, Hallemeier CL. Utility of (18)F-FDG PET for Predicting Histopathologic Response in Esophageal Carcinoma following Chemoradiation. J Thorac Oncol. 2017 Jan; 12 (1):121-128 Epub 2016 Aug 26
    View PubMed
  5. Biswas T, Efird JT, Prasad S, James SE, Walker PR, Zagar TM. Inflammatory TNBC Breast Cancer: Demography and Clinical Outcome in a Large Cohort of Patients With TNBC. Clin Breast Cancer. 2016 Jun; 16: (3)212-6.
    View PubMed
  6. Prasad S, Efird JT, James SE, Walker PR, Zagar TM, Biswas T. Failure patterns and survival outcomes in triple negative breast cancer (TNBC): a 15 year comparison of 448 non-Hispanic black and white women. Springerplus. 2016; 5 (1):756 Epub 2016 June 17
    View PubMed
  7. He Y, Han JR, Chang O, Oh M, James SE, Lu Q, Seo YW, Kim H, Kim K. 14-3-3varepsilon/zeta Affects the stability of delta-catenin and regulates delta-catenin-induced dendrogenesis. FEBS Open Bio. 2013; 3:16-21.
    View PubMed
  8. James SE, Dunham M, Carrion-Jones M, Murashov A, Lu Q. Rho kinase inhibitor Y-27632 facilitates recovery from experimental peripheral neuropathy induced by anti-cancer drug cisplatin. Neurotoxicology. 2010 Mar; 31: (2)188-94.
    View PubMed
  9. Dunham MW, James SE, Lever TE, Lu Q, Carrion-Jones MJ. Methodology to obtain a mixed sural nerve recording in mice. Am J Phys Med Rehabil. 2009 Jul; 88: (7)542-6.
    View PubMed
  10. James SE, Burden H, Burgess R, Xie Y, Yang T, Massa SM, Longo FM, Lu Q. Anti-cancer drug induced neurotoxicity and identification of Rho pathway signaling modulators as potential neuroprotectants. Neurotoxicology. 2008 Jul; 29: (4)605-12.
    View PubMed
  11. Kim H, Han JR, Park J, Oh M, James SE, Chang S, Lu Q, Lee KY, Ki H, Song WJ, Kim K. Delta-catenin-induced dendritic morphogenesis. An essential role of p190RhoGEF interaction through Akt1-mediated phosphorylation. J Biol Chem. 2008 Jan 11; 283: (2)977-87.
    View PubMed